Teva Pharmaceutical's Investment Opportunities and Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Should l Buy TEVA?
Source: Fool
- Increased Market Competition: Teva Pharmaceutical's generics business faces intensifying competition, leading to declining profits; although the company excels in complex generics, it requires more investment and entails higher risks.
- Risky Business Transformation: Teva is not only focusing on generics but also developing original drugs, which presents opportunities for success but also exposes the company to significant competition from more experienced firms, increasing business uncertainty.
- Financial Performance Overview: With a market cap of $39 billion and a current stock price of $33.85, Teva's gross margin stands at 51.82%, indicating profitability in the generics market, yet market confidence in its future growth remains low.
- Cautious Investor Sentiment: While Teva's business model attracts some investors, conservative investors may be wary of the risks associated with its transformation, particularly in the highly competitive pharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.500
Low
29.00
Averages
35.71
High
40.00
Current: 31.500
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Long-Term Investment Opportunities Amid Market Volatility
- Brookfield Corporation Undervalued: Brookfield Corporation, with a market cap of $105 billion, has seen its stock drop 2.99% amid market volatility; however, it is projected to achieve over 20% earnings growth in the next five years, potentially closing the valuation gap of its holdings and driving stock appreciation.
- SSR Mining Benefits from Rising Gold Prices: As geopolitical tensions escalate, gold prices have surged again, leading SSR Mining's stock to hit new highs; with adjusted earnings expected to grow significantly due to high gold prices, the stock currently trades at less than 9 times forward earnings, indicating strong investment potential.
- Teva Pharmaceuticals' Ongoing Transformation: Israel-based Teva Pharmaceuticals is transitioning from a generic drugmaker to a branded pharmaceutical company, with its branded drug business growing at a mid-double-digit rate; as its drug pipeline advances, steady sales and profitability growth are expected, with a current forward P/E of 12.5 that could rise to the mid-teens.
- Market Trends and Investment Opportunities: Despite multiple challenges in the market, certain stocks are benefiting from trends like rising gold prices and the adoption of generative AI; even with just $1,000, investors can consider these stocks, which may yield substantial long-term returns.
See More
Comparing Turnarounds: Pfizer vs. Teva
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.3%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it more appealing to income-focused investors.
- Pfizer's Challenges and Responses: Facing key patent expirations and setbacks in new drug development, Pfizer has strategically acquired a promising GLP-1 drug candidate, demonstrating its resilience and ability to thrive amid industry fluctuations.
- Teva's Turnaround Risks: Teva is undergoing a significant business transformation to include both generics and new drugs, which increases its risk profile, especially as it currently does not offer dividends to attract income-seeking investors.
- Investor Choice: For turnaround investors, Pfizer may represent a superior option, particularly for those who value dividends, as Teva's business overhaul presents greater challenges compared to the typical industry headwinds Pfizer is navigating.
See More
Druckenmiller Cuts Pharma and Semiconductor Holdings
- Selling Top Performers: In his latest 13F filing, Druckenmiller reduced his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% cut, and also sold 222,000 shares of Taiwan Semiconductor Manufacturing (TSMC), a 29% reduction, indicating a cautious outlook on the future performance of these stocks.
- Teva's Financial Improvement: Under CEO Richard Francis, Teva has focused on high-margin novel drug development, leading to significant sales growth, with its stock price doubling since Druckenmiller's initial investment in Q3 2024, reflecting improved financial flexibility after years of cost-cutting and asset sales.
- TSMC's AI Advantage: TSMC, the world's leading chip fabricator, has also seen its stock price double since Druckenmiller opened a position, benefiting from its chip technology being a staple in AI-accelerated data centers, highlighting its critical role in the rapidly evolving tech landscape.
- New Investment Focus: Druckenmiller's 13F report revealed a purchase of 5,495,600 shares of the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling optimism about the U.S. economic recovery, despite the Federal Reserve's easing cycle since September 2024, which could impact financial stocks' performance.
See More
Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks
- Pharmaceutical Stake Reduction: Druckenmiller cut his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% reduction, reflecting a profit-taking strategy after significant stock appreciation, indicating a cautious outlook on the pharmaceutical sector's future.
- Semiconductor Stake Cut: He also reduced his position in Taiwan Semiconductor by 222,000 shares, a 29% decrease, likely due to concerns over the stock's overheated performance amid the AI revolution, showcasing his sensitivity to market fluctuations.
- ETF Investment Increase: Druckenmiller purchased 5,495,600 shares of the State Street Financial Select Sector SPDR ETF, making it the fund's second-largest holding, signaling optimism about the U.S. economic recovery, particularly as rising interest rates could enhance financial sector profitability.
- Portfolio Dynamics: With an average holding period of 7.5 months for securities in his portfolio, Druckenmiller demonstrates a flexible investment strategy and rapid responsiveness to market changes, suggesting a keen awareness of future market trends.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Blackstone and Teva Forge $400M Strategic Funding Agreement
- Strategic Funding Agreement: Blackstone Life Sciences has secured a $400 million strategic funding agreement with Teva Pharmaceutical to support the development of duvakitug, a phase 3 asset for ulcerative colitis and Crohn's disease, with funds allocated over four years.
- Milestone Payment Structure: Teva will pay Blackstone a milestone payment upon duvakitug's approval, and Blackstone is also eligible for commercial milestones and low single-digit royalties on global sales, enhancing its revenue potential significantly.
- Co-Development and Commercialization: Duvakitug will be co-developed and co-commercialized with Sanofi, a partnership that not only facilitates resource sharing but also accelerates the product's market entry, thereby improving competitive positioning.
- Clinical Data Support: Teva and Sanofi released phase 2b maintenance data on duvakitug in February, demonstrating the drug's potential in treating inflammatory bowel disease, which lays a solid foundation for subsequent clinical development.
See More
Long-Term Investment Opportunities Amid Market Volatility
- Brookfield Corporation Undervalued: Brookfield Corporation, with a market cap of $105 billion, has seen its stock drop 2.99% amid market volatility; however, it is projected to achieve over 20% earnings growth in the next five years, potentially closing the valuation gap of its holdings and driving stock appreciation.
- SSR Mining Benefits from Rising Gold Prices: As geopolitical tensions escalate, gold prices have surged again, leading SSR Mining's stock to hit new highs; with adjusted earnings expected to grow significantly due to high gold prices, the stock currently trades at less than 9 times forward earnings, indicating strong investment potential.
- Teva Pharmaceuticals' Ongoing Transformation: Israel-based Teva Pharmaceuticals is transitioning from a generic drugmaker to a branded pharmaceutical company, with its branded drug business growing at a mid-double-digit rate; as its drug pipeline advances, steady sales and profitability growth are expected, with a current forward P/E of 12.5 that could rise to the mid-teens.
- Market Trends and Investment Opportunities: Despite multiple challenges in the market, certain stocks are benefiting from trends like rising gold prices and the adoption of generative AI; even with just $1,000, investors can consider these stocks, which may yield substantial long-term returns.
See More
Comparing Turnarounds: Pfizer vs. Teva
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.3%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it more appealing to income-focused investors.
- Pfizer's Challenges and Responses: Facing key patent expirations and setbacks in new drug development, Pfizer has strategically acquired a promising GLP-1 drug candidate, demonstrating its resilience and ability to thrive amid industry fluctuations.
- Teva's Turnaround Risks: Teva is undergoing a significant business transformation to include both generics and new drugs, which increases its risk profile, especially as it currently does not offer dividends to attract income-seeking investors.
- Investor Choice: For turnaround investors, Pfizer may represent a superior option, particularly for those who value dividends, as Teva's business overhaul presents greater challenges compared to the typical industry headwinds Pfizer is navigating.
See More
Druckenmiller Cuts Pharma and Semiconductor Holdings
- Selling Top Performers: In his latest 13F filing, Druckenmiller reduced his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% cut, and also sold 222,000 shares of Taiwan Semiconductor Manufacturing (TSMC), a 29% reduction, indicating a cautious outlook on the future performance of these stocks.
- Teva's Financial Improvement: Under CEO Richard Francis, Teva has focused on high-margin novel drug development, leading to significant sales growth, with its stock price doubling since Druckenmiller's initial investment in Q3 2024, reflecting improved financial flexibility after years of cost-cutting and asset sales.
- TSMC's AI Advantage: TSMC, the world's leading chip fabricator, has also seen its stock price double since Druckenmiller opened a position, benefiting from its chip technology being a staple in AI-accelerated data centers, highlighting its critical role in the rapidly evolving tech landscape.
- New Investment Focus: Druckenmiller's 13F report revealed a purchase of 5,495,600 shares of the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling optimism about the U.S. economic recovery, despite the Federal Reserve's easing cycle since September 2024, which could impact financial stocks' performance.
See More
Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks
- Pharmaceutical Stake Reduction: Druckenmiller cut his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% reduction, reflecting a profit-taking strategy after significant stock appreciation, indicating a cautious outlook on the pharmaceutical sector's future.
- Semiconductor Stake Cut: He also reduced his position in Taiwan Semiconductor by 222,000 shares, a 29% decrease, likely due to concerns over the stock's overheated performance amid the AI revolution, showcasing his sensitivity to market fluctuations.
- ETF Investment Increase: Druckenmiller purchased 5,495,600 shares of the State Street Financial Select Sector SPDR ETF, making it the fund's second-largest holding, signaling optimism about the U.S. economic recovery, particularly as rising interest rates could enhance financial sector profitability.
- Portfolio Dynamics: With an average holding period of 7.5 months for securities in his portfolio, Druckenmiller demonstrates a flexible investment strategy and rapid responsiveness to market changes, suggesting a keen awareness of future market trends.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Blackstone and Teva Forge $400M Strategic Funding Agreement
- Strategic Funding Agreement: Blackstone Life Sciences has secured a $400 million strategic funding agreement with Teva Pharmaceutical to support the development of duvakitug, a phase 3 asset for ulcerative colitis and Crohn's disease, with funds allocated over four years.
- Milestone Payment Structure: Teva will pay Blackstone a milestone payment upon duvakitug's approval, and Blackstone is also eligible for commercial milestones and low single-digit royalties on global sales, enhancing its revenue potential significantly.
- Co-Development and Commercialization: Duvakitug will be co-developed and co-commercialized with Sanofi, a partnership that not only facilitates resource sharing but also accelerates the product's market entry, thereby improving competitive positioning.
- Clinical Data Support: Teva and Sanofi released phase 2b maintenance data on duvakitug in February, demonstrating the drug's potential in treating inflammatory bowel disease, which lays a solid foundation for subsequent clinical development.
See More
